The tumor lineage and aggressive potential was confirmed by extensive genetic testing revealing a high tumor mutational burden and pathogenic mutations in TERT, NRAS, and NF1, alongside alterations in PBRM1 and FAT1, which may contribute to the tumor's unique morphology. This evidence concerns the gene NRAS and neoplasm.